Blog dedicated to the continuous education in Gynecology and Endocrinology


<- Back to home

Use of venlafaxine in psychiatric disorders and climacteric syndrome: is a therapeutic bridge ?

DGYE-2011-0023.R1 4

Luisi Stefano; Castrogiovanni Andrea; Ciani Valentina; Pacchierotti Claudia; De Capua Alberto; Pasquini Raffaele; Lazzeri Lucia; Petraglia Felice

Objective: to verify the efficacy of the double action mechanism of venlafaxine for depression and climacteric symptoms.

Methods: a group of twenty postmenopausal women (age range 40-60 years) with diagnosis of Major Depressive Disorder, Generalized Anxiety Disorder and climacteric symptoms was enrolled. All participants received vennlafaxine (75 mg/day) for two months. Clinical check-up and evaluation test were repeated every two weeks for two months of treatment.

Results: before treatment the mean scores for the clinical evaluation scales (Hamilton Depression Rating Scale and Hamilton Anxiety Rating Scale) were 13.9 and 18.7 respectively (mild-moderate severity). The general level of psychopathology was not particularly high (Symptomatology Check list-90 mean total 103), the most common psychopathological dimension were depression and somatisation. The sample suffered from mild climacteric syndrome (Kupperman Index Score mean=19.1).

Clinical improvement was visible after two weeks of treatment and continued until the last check-up, two months after the start of treatment (final Hamilton Depression Rating Scale and Hamilton Anxiety Rating Scale scores: 5.1 and 6.3 respectively). Kupperman Index Scores at the end of the treatment period demonstrated complete resolution of the climacteric syndrome (mean score=6.57).

Conclusion: venlafaxine is efficacy in treating both psychiatric disorders and climacteric symptomatology.

Post to Twitter Post to Facebook

< Back to home page

© International Society of Gynecological Endocrinology - Privacy Policy